<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00479752</url>
  </required_header>
  <id_info>
    <org_study_id>CECOG /CORE 1.2.002</org_study_id>
    <nct_id>NCT00479752</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Folfox4 + Weekly Cetuximab vs Folfox 4+Biweekly Cetuximab by Metastatic Colorectal Cancer</brief_title>
  <acronym>CORE 2</acronym>
  <official_title>A Randomized, Open-label Phase II Study Evaluating the Efficacy and Safety of FOLFOX4 + Weekly Cetuximab Versus FOLFOX4+ Biweekly Cetuximab as First-line Therapy in Patients With Metastatic Colorectal Cancer.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Central European Cooperative Oncology Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Central European Cooperative Oncology Group</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To assess the efficacy of FOLFOX4 in combination with cetuximab, weekly and FOLFOX4 in
      combination with cetuximab, biweekly.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This multicenter randomized phase II study will enroll approximately 150 patients with
      metastatic Colorectal Cancer. Patients are randomized in Arm A(FOLFOX4 in combination with
      weekly Cetuximab) or Arm B (FOLFOX4 in combination with biweekly Cetuximab). Both efficacy
      and safety data will be collected. The investigator will assess response to treatment every 8
      weeks based on the imaging.

      Following permanent treatment cessation, patients will be followed-up for survival.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2008</start_date>
  <completion_date type="Actual">November 2015</completion_date>
  <primary_completion_date type="Actual">June 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary endpoint of the trial is: • Objective response (CR/PR), as assessed by RECIST criteria</measure>
    <time_frame>The objective response rate - defined as the rate of subjects with complete response (CR) or partial response (PR)</time_frame>
    <description>Objective response (partial or complete) will be assessed using RECIST criteria. The objective response rate (defined as the rate of subjects with complete response (CR) or partial response (PR)) will be estimated and associated exact two-sided 95% confidence limit (Clopper-Pearson) will be calculated. In addition to the estimates within each treatment group odds ratios and associated 95% CI will be calculated using the Cochran Mantel-Haenszel procedure.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>• Progression Free Survival (PFS) • Overall survival • Safety/Adverse events Safety</measure>
    <time_frame>he rate of subjects with complete response (CR) or partial response (PR)</time_frame>
    <description>Secondary objectives are the estimation of differences in PFS and overall survival.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">151</enrollment>
  <condition>Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>FOLFOX4:
Oxaliplatin 85 mg/m² d1
Leucovorin 200 mg/m² d1+d2, followed by
Bolus 5FU 400 mg/m², followed by
Infusional 5FU 600 mg/m²,over 22 hours, every 2 weeks
Cetuximab is administered to arm A of the study as an infusion with initial dose 400 mg/m² in week 1 followed by weekly doses of 250 mg/m².</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>FOLFOX4:
Oxaliplatin 85 mg/m² d1
Leucovorin 200 mg/m² d1+d2, followed by
Bolus 5FU 400 mg/m² , followed by
Infusional 5FU 600 mg/m², over 22 hours, every 2 weeks
Cetuximab is administered to arm B of the study as infusions of 500 mg/m² every two weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FOLFOX4 (Oxaliplatin), Cetuximab</intervention_name>
    <description>Arm A FOLFOX4:
Oxaliplatin 85 mg/m² d1
Leucovorin 200 mg/m² d1+d2, followed by
Bolus 5FU 400 mg/m², followed by
Infusional 5FU 600 mg/m²,over 22 hours, every 2 weeks
Cetuximab is administered to arm A of the study as an infusion with initial dose 400 mg/m² in week 1 followed by weekly doses of 250 mg/m².
Arm B FOLFOX4:
Oxaliplatin 85 mg/m² d1
Leucovorin 200 mg/m² d1+d2, followed by
Bolus 5FU 400 mg/m² , followed by
Infusional 5FU 600 mg/m², over 22 hours, every 2 weeks
Cetuximab is administered to arm B of the study as infusions of 500 mg/m² every two weeks.</description>
    <arm_group_label>A</arm_group_label>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed written informed consent

          -  Male or female ≥ 18 years of age

          -  Diagnosis of histologically confirmed adenocarcinoma of the colon or rectum

          -  Metastatic colorectal carcinoma not suitable for curative-intent resection-
             Availability of tumor sample (or able and willing to provide tumor sample) for EGFR
             assessment

          -  Presence of at least one lesion measurable unidimensionally by CT scan or MRI. (Target
             lesion(s) must not lie within an irradiated area)

          -  Karnofsky performance status of &gt; 80 at study entry

          -  Leucocytes ≥ 3.0 x 10 9/L and neutrophils ≥1.5 x 10 9/L, platelets ≥ 100 x 10 9/L, and
             hemoglobin ≥ 9 g/dL.

          -  Bilirubin ≥ 1.5 x ULN

          -  ASAT and ALAT ≤ 2.5 x ULN (≤5 x ULN if liver metastasis are present)

          -  Serum creatinine ≤ 1.5 x ULN

        Exclusion Criteria:

          -  Brain metastasis (known or suspected)

          -  Previous chemotherapy for metastatic disease. Prior adjuvant chemotherapy is allowed
             if the chemotherapy treatment free interval is &gt; 6 months.

          -  Surgery (excluding diagnostic biopsy) or irradiation within 4 weeks prior to study
             entry

          -  Concurrent chronic systemic immune therapy, chemotherapy, or hormone therapy not
             indicated in the study protocol

          -  Any investigational agent(s) within 4 weeks prior to entry

          -  Previous exposure to EGFR-pathway targeting therapy

          -  Clinically relevant coronary artery disease or a history of a myocardial infarction
             within the last 12 months

          -  Acute or subacute intestinal occlusion or history of inflammatory bowel disease

          -  Pre-existing neuropathy &gt; grade 1. In case of prior oxaliplatin containing adjuvant
             chemotherapy: pre-existing neuropathy ≥ 1.

          -  Known grade 3 or 4 allergic reaction to any of the components of the treatment.

          -  Any concurrent malignancy other than non-melanoma skin cancer, or carcinoma in situ of
             the cervix. (Patients with a previous malignancy but without evidence of disease for ≥
             5 years will be allowed to enter the trial)

          -  Pregnancy or lactation

          -  Inadequate contraception (male or female patients) if of childbearing or procreational
             potential

          -  Known drug abuse/ alcohol abuse

          -  Legal incapacity or limited legal capacity

          -  Medical or psychological condition which in the opinion of the investigator would not
             permit the patient to complete the study or sign meaningful informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tudor Ciuleanu, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institutul Oncologic of Cluj</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>LKH Leoben, Abt. für Innere Medizin</name>
      <address>
        <city>Leoben</city>
        <state>Steiermark</state>
        <zip>8700</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University of Vienna</name>
      <address>
        <city>Vienna</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute of Oncology Sarajevo</name>
      <address>
        <city>Sarajevo</city>
        <country>Bosnia and Herzegovina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SBALO National Oncology Center</name>
      <address>
        <city>Sofia</city>
        <zip>1754</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Centre Rijeka</name>
      <address>
        <city>Rijeka</city>
        <zip>51000</zip>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital for Tumors</name>
      <address>
        <city>Zagreb</city>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Rebro</name>
      <address>
        <city>Zagreb</city>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Noth estonian Regional Oncology Hospital</name>
      <address>
        <city>Tallin</city>
        <zip>13419</zip>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AHEPA Hospital University Hospital Papageorgiou</name>
      <address>
        <city>Athens</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>General Hospital of Athens</name>
      <address>
        <city>Athens</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Semmelweis Univ. Radiology Clinic</name>
      <address>
        <city>Budapest</city>
        <zip>1082</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Medical Center</name>
      <address>
        <city>Budapest</city>
        <zip>1135</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Markusovsy Hospital</name>
      <address>
        <city>Szombathely</city>
        <zip>39700</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Meir Medical Center</name>
      <address>
        <city>Kfar Saba</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oncology Division Sourasky Medical Center</name>
      <address>
        <city>Tel Aviv</city>
        <zip>64239</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>P. Stradins University Hospital</name>
      <address>
        <city>Riga</city>
        <zip>1020</zip>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>latvian Center of Oncology</name>
      <address>
        <city>Riga</city>
        <zip>1079</zip>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institutul Oncologic Bucuresti</name>
      <address>
        <city>Bucuresti</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institutul Oncologic Ion Chiricuta</name>
      <address>
        <city>Cluj Napoca</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute of Oncology and Radiology of Serbia</name>
      <address>
        <city>Belgrade</city>
        <zip>11000</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute of Oncology of Vojvodina</name>
      <address>
        <city>Sremska Kamenica</city>
        <zip>21204</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Cancer Institute</name>
      <address>
        <city>Bratislava</city>
        <zip>83310</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Institute of Oncology</name>
      <address>
        <city>Bratislava</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute of Oncology</name>
      <address>
        <city>Ljubljana</city>
        <zip>1000</zip>
        <country>Slovenia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Bosnia and Herzegovina</country>
    <country>Bulgaria</country>
    <country>Croatia</country>
    <country>Estonia</country>
    <country>Greece</country>
    <country>Hungary</country>
    <country>Israel</country>
    <country>Latvia</country>
    <country>Romania</country>
    <country>Serbia</country>
    <country>Slovakia</country>
    <country>Slovenia</country>
  </location_countries>
  <removed_countries>
    <country>Cyprus</country>
    <country>Former Serbia and Montenegro</country>
  </removed_countries>
  <verification_date>February 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 25, 2007</study_first_submitted>
  <study_first_submitted_qc>May 25, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 28, 2007</study_first_posted>
  <last_update_submitted>February 17, 2016</last_update_submitted>
  <last_update_submitted_qc>February 17, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 18, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Cetuximab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

